Accuray (ARAY) Competitors

AngioDynamics (NASDAQ:ANGO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

Does the media favor ANGO or ARAY?

In the previous week, AngioDynamics had 1 more articles in the media than Accuray. MarketBeat recorded 3 mentions for AngioDynamics and 2 mentions for Accuray. AngioDynamics' average media sentiment score of 0.95 beat Accuray's score of 0.90 indicating that Accuray is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AngioDynamics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ANGO or ARAY?

AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.

Company	Underperform	Outperform
AngioDynamics	Outperform Votes 361 60.67%	Underperform Votes 234 39.33%
Accuray	Outperform Votes 331 65.67%	Underperform Votes 173 34.33%

Do insiders and institutionals believe in ANGO or ARAY?

89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 5.1% of AngioDynamics shares are owned by company insiders. Comparatively, 3.8% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more volatility & risk, ANGO or ARAY?

AngioDynamics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Do analysts rate ANGO or ARAY?

AngioDynamics currently has a consensus target price of $14.25, indicating a potential upside of 132.46%. Accuray has a consensus target price of $8.25, indicating a potential upside of 275.00%. Given AngioDynamics' higher possible upside, analysts plainly believe Accuray is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Accuray	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, ANGO or ARAY?

Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$338.75M	0.72	-$52.44M	-$4.84	-1.27
Accuray	$447.48M	0.48	-$9.28M	-$0.15	-14.53

Is ANGO or ARAY more profitable?

Accuray has a net margin of -3.25% compared to Accuray's net margin of -60.21%. Accuray's return on equity of -3.48% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-60.21%	-3.48%	-2.68%
Accuray	-3.25%	-28.11%	-3.05%

Summary

AngioDynamics beats Accuray on 9 of the 17 factors compared between the two stocks.